100 related articles for article (PubMed ID: 28918930)
1. A parenteral docetaxel-loaded lipid microsphere with decreased 7-epidocetaxel conversion in vitro and in vivo.
Luo L; Wang X; Chen Q; Miao L; Zhuo X; Liu L; Xu J; Zhang Y; He H; Yin T; Tang X
Eur J Pharm Sci; 2017 Nov; 109():638-649. PubMed ID: 28918930
[TBL] [Abstract][Full Text] [Related]
2. Is an alternative drug delivery system needed for docetaxel? The role of controlling epimerization in formulations and beyond.
Manjappa AS; Goel PN; Vekataraju MP; Rajesh KS; Makwana K; Ukawala M; Nikam Y; Gude RP; Murthy RS
Pharm Res; 2013 Oct; 30(10):2675-93. PubMed ID: 23756759
[TBL] [Abstract][Full Text] [Related]
3. PEGylated lipid microspheres loaded with cabazitaxel for intravenous administration: stability, bioavailability, antitumor efficacy, and toxicity.
Liu Y; Xie B; Li L; Zhang X; Zhang Y; He H; Yin T; Tang X; Cai C; Gou J
Drug Deliv Transl Res; 2018 Oct; 8(5):1365-1379. PubMed ID: 30019282
[TBL] [Abstract][Full Text] [Related]
4. Parenteral formulation of larotaxel lipid microsphere tackling poor solubility and chemical instability.
Teng F; Yang H; Li G; Lin X; Zhang Y; Tang X
Int J Pharm; 2014 Jan; 460(1-2):212-9. PubMed ID: 24184034
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue distribution of docetaxel by liquid chromatography-mass spectrometry: evaluation of folate receptor-targeting amphiphilic copolymer modified nanostructured lipid carrier.
Zhao X; Zhao Y; Geng L; Li X; Wang X; Liu Z; Wang D; Bi K; Chen X
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Dec; 879(31):3721-7. PubMed ID: 22035980
[TBL] [Abstract][Full Text] [Related]
6. Evidence for the conversion of docetaxel into 7'-epidocetaxel in patients receiving Taxotere-based conventional chemotherapy.
Czejka M; Greil R; Ulsperger E; Schnait H; Kienesberger K; Brumnik T; Farkouh A; Schierholz J
Int J Clin Pharmacol Ther; 2010 Jul; 48(7):483-4. PubMed ID: 20557853
[No Abstract] [Full Text] [Related]
7. Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1α.
Qi Y; Liu G
Drug Deliv; 2021 Dec; 28(1):171-182. PubMed ID: 33427515
[TBL] [Abstract][Full Text] [Related]
8. Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles.
Zhigaltsev IV; Winters G; Srinivasulu M; Crawford J; Wong M; Amankwa L; Waterhouse D; Masin D; Webb M; Harasym N; Heller L; Bally MB; Ciufolini MA; Cullis PR; Maurer N
J Control Release; 2010 Jun; 144(3):332-40. PubMed ID: 20202473
[TBL] [Abstract][Full Text] [Related]
9. Preparation, characterization and pharmacokinetics of N-palmitoyl chitosan anchored docetaxel liposomes.
Liang G; Jia-Bi Z; Fei X; Bin N
J Pharm Pharmacol; 2007 May; 59(5):661-7. PubMed ID: 17524231
[TBL] [Abstract][Full Text] [Related]
10. Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats.
Pawar H; Surapaneni SK; Tikoo K; Singh C; Burman R; Gill MS; Suresh S
Drug Deliv; 2016 May; 23(4):1453-68. PubMed ID: 26878325
[TBL] [Abstract][Full Text] [Related]
11. Formulation, preparation and evaluation of flunarizine-loaded lipid microspheres.
Wang YJ; Wang J; Zhang HY; He HB; Tang X
J Pharm Pharmacol; 2007 Mar; 59(3):351-7. PubMed ID: 17331337
[TBL] [Abstract][Full Text] [Related]
12. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting.
Tiantian Y; Wenji Z; Mingshuang S; Rui Y; Shuangshuang S; Yuling M; Jianhua Y; Xinggang Y; Shujun W; Weisan P
Int J Pharm; 2014 Aug; 471(1-2):245-57. PubMed ID: 24858386
[TBL] [Abstract][Full Text] [Related]
13. Preparation and pharmacokinetics of docetaxel based on nanostructured lipid carriers.
Li X; Wang D; Zhang J; Pan W
J Pharm Pharmacol; 2009 Nov; 61(11):1485-92. PubMed ID: 19903373
[TBL] [Abstract][Full Text] [Related]
14. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation.
Nassar T; Attili-Qadri S; Harush-Frenkel O; Farber S; Lecht S; Lazarovici P; Benita S
Cancer Res; 2011 Apr; 71(8):3018-28. PubMed ID: 21363913
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery.
Fan X; Chen J; Shen Q
Int J Pharm; 2013 Dec; 458(2):296-304. PubMed ID: 24177313
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal stability, physicochemical characterization and oral bioavailability of chitosan or its derivative-modified solid lipid nanoparticles loading docetaxel.
Shi LL; Lu J; Cao Y; Liu JY; Zhang XX; Zhang H; Cui JH; Cao QR
Drug Dev Ind Pharm; 2017 May; 43(5):839-846. PubMed ID: 27487431
[TBL] [Abstract][Full Text] [Related]
17. Stable and efficient delivery of docetaxel by micelle-encapsulation using a tripodal cyclotriphosphazene amphiphile.
Jun YJ; Jadhav VB; Min JH; Cui JX; Chae SW; Choi JM; Kim IS; Choi SJ; Lee HJ; Sohn YS
Int J Pharm; 2012 Jan; 422(1-2):374-80. PubMed ID: 22079718
[TBL] [Abstract][Full Text] [Related]
18. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study.
Fang G; Tang B; Chao Y; Xu H; Gou J; Zhang Y; Xu H; Tang X
Mol Pharm; 2015 Jul; 12(7):2384-95. PubMed ID: 25974386
[TBL] [Abstract][Full Text] [Related]
19. Unravelling the anticancer efficacy of 10-oxo-7-epidocetaxel: in vitro and in vivo results.
Manjappa AS; Ramachandra Murthy RS
Drug Dev Ind Pharm; 2019 Mar; 45(3):474-484. PubMed ID: 30599774
[TBL] [Abstract][Full Text] [Related]
20. Highly efficient and lowly toxic docetaxel nanoemulsions for intravenous injection to animals.
Li X; Du L; Wang C; Liu Y; Mei X; Jin Y
Pharmazie; 2011 Jul; 66(7):479-83. PubMed ID: 21812321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
